May 23 Financial Quick Takes: NYSE to lower fees for biotechs; plus Guardant and more

NYSE proposes lower fees for prerevenue biotechs
For biotech companies with a market cap of at least $200 million and annual revenues of $5 million or less, the New York Stock Exchange proposed in an SEC filing on May 16 to cap total fees at $25,000 for the fiscal quarter in which the company lists and in each of the 12 following fiscal quarters, down from the $500,000 per year fee cap.

Guardant raises $319.5M follow-on
Liquid biopsy company Guardant Health Inc. (NASDAQ:GH) raised $319.5 million through the sale of 4.5 million shares at $71 in follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Cowen and William Blair...